121,550 Shares in Certara, Inc. (NASDAQ:CERT) Purchased by Vontobel Holding Ltd.

Vontobel Holding Ltd. purchased a new position in Certara, Inc. (NASDAQ:CERT - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 121,550 shares of the company's stock, valued at approximately $1,295,000. Vontobel Holding Ltd. owned about 0.08% of Certara as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Brown Brothers Harriman & Co. bought a new stake in shares of Certara in the 3rd quarter valued at about $27,292,000. Kopion Asset Management LLC boosted its stake in shares of Certara by 46.0% during the fourth quarter. Kopion Asset Management LLC now owns 555,643 shares of the company's stock valued at $5,918,000 after purchasing an additional 175,005 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of Certara by 40.7% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,901,898 shares of the company's stock worth $45,691,000 after purchasing an additional 1,128,006 shares during the last quarter. Barclays PLC increased its stake in shares of Certara by 198.3% in the third quarter. Barclays PLC now owns 70,525 shares of the company's stock worth $825,000 after buying an additional 46,880 shares during the period. Finally, Advantage Alpha Capital Partners LP bought a new stake in Certara during the 3rd quarter valued at $1,875,000. 73.96% of the stock is currently owned by hedge funds and other institutional investors.

Certara Trading Down 2.8 %

CERT stock traded down $0.38 during trading on Friday, reaching $13.17. The company had a trading volume of 1,022,969 shares, compared to its average volume of 1,265,069. The business has a 50 day moving average of $12.32 and a 200 day moving average of $11.66. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company has a market cap of $2.12 billion, a P/E ratio of -65.85, a PEG ratio of 9.62 and a beta of 1.57. Certara, Inc. has a 52 week low of $9.41 and a 52 week high of $19.87.

Analysts Set New Price Targets

A number of equities analysts have issued reports on CERT shares. Barclays decreased their price objective on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating on the stock in a research report on Thursday, November 7th. Robert W. Baird lowered their price target on Certara from $18.00 to $13.00 and set a "neutral" rating for the company in a research report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus price target of $15.92.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.